专利号:US-2003050305-A1 优先权日:2000-05-22 标题:Thromboxane inhibitors, compositions and methods of use 发明人:TEJADA INIGO SAENZ DE 摘要:The present invention describes methods for treating or preventing sexual dysfunctions in males and females, and for enhancing sexual responses in males and females by administering a therapeutically effective amount of at least one thromboxane inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The male or female may preferably be diabetic. The present invention also provides novel compositions comprising at least one thromboxane inhibitor, and, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and, optionally, at least one therapeutic agent, such as, vasoactive agents, nonsteroidal antiinflanmmatory compounds (NSAIDs), selective cyclooxygenase-2 (COX-2) inhibitors, anticoagulants, angiotensin converting enzymes (ACE) inhibitors, angiotensin II receptor antagonists, renin inhibitors, and mixtures thereof. The present invention also provides methods for treating or preventing ischemic heart disorders, myocardial infarction, angina pectoris, stroke, migraine, cerebral hemorrhage, cardiac fatalities, transient ischaemic attacks, complications following organ transplants, coronary artery bypasses, angioplasty, endarterectomy, atherosclerosis, pulmonary embolism, bronchial asthma, bronchitis, pneumonia, circulatory shock of various organs, nephritis, graft rejection, cancerous metastases, pregnancy-induced hypertension, preeclampsia, eclampsia, thrombotic and thromboembolic disorders, intrauterine growth, gastrointestinal disorders, renal diseases and disorders, disorders resulting from elevated uric acid levels and dysmenorrhea, and for inhibiting platelet aggregation or platelet adhesion or relaxing smooth muscles.
专利号:JP-2004500344-A 优先权日:1999-10-29 标 题 :Synthesis of endogenous nitric oxide under low oxygen partial pressure
专利号:US-8076315-B2 优先权日:2005-10-14 标题:Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists 发明人:CARLEY DAVID W; RADULOVACKI MIODRAG 权利人:CARLEY DAVID W; RADULOVACKI MIODRAG; UNIV ILLINOIS 摘要:This invention is directed to methods for preventing or ameliorating sleep-related breathing disorders. The method comprises administration to a patient in need thereof an effective dose of one or a combination of prostanoid receptor antagonists (eg. ramatroban, ifetroban, diphloretin, phosphate, polyphloretin phosphate, seratrodast, SC19220). The prostanoid receptor antagonist or combination of prostanoid receptor antagonists can be administered in conjunction with one or more serotonin receptor agonists, one or more cannabinoids receptor agonists, one or more serotonin reuptake inhibitors, one or more noradrenalin reuptake inhibitors, a combination of reuptake inhibitors, an inhibitor of prostanoid synthesis, or any combination of the foregoing.
专利号:EP-1242068-A1 优先权日:1999-10-29 标 题:Endogenous nitric oxide synthesis under conditions of low oxygen tension
专利号:AU-1342901-A 优先权日:1999-10-29 标 题 :Endogenous nitric oxide synthesis under conditions of low oxygen tension
专利号:WO-0132167-A1 优先权日:1999-10-26 标题:Endogenous nitric oxide synthesis under conditions of low oxygen tension
1: Lou B. Crystal structure of 7-phenyl-7-(2,4,5-trimethyl-3,6-dioxo-cyclo-hexa-1,4-dien-1-yl)hepta-noate 1,3-dihy-droxy-2-(hy-droxy-meth-yl)propan-2-aminium monohydrate: a new solid form of seratrodast. Acta Crystallogr Sect E Struct Rep Online. 2014 Sep 20;70(Pt 10):228-30. doi: 10.1107/S1600536814020625. 2: Kuninobu Y, Kawata A, Noborio T, Yamamoto S, Matsuki T, Takata K, Takai K. Indium-catalyzed synthesis of keto esters from cyclic 1,3-diketones and alcohols and application to the synthesis of seratrodast. Chem Asian J. 2010 Apr 1;5(4):941-5. doi: 10.1002/asia.200900553. doi: 10.1016/j.jpba.2008.05.002. Chinese. Japanese. Review. Japanese.
合成参考文献
摘要:Muramatsu H, Kotajima R, Sato T. [Correlation between the clinical effects of Seratrodast and the level of 11-dehydrothromboxane B2 in urine/sputum in bronchial asthma patients]. Arerugi. 2001 Jun;50(6):540–6. 参考文献:10.1007/s004320050291 摘要:Fujimura M, Kasahara K, Shirasaki H, Heki U, Iwasa K, Ueda A, Matsuda T. Up-regulation of ICH-1l protein by thromboxane A2 antagonists enhances cisplatin-induced apoptosis in non-small-cell lung-cancer cell lines. Journal of Cancer Research and Clinical Oncology. 1999 Jun;125(7):389–94. doi: 10.1007/s004320050291. 参考文献:10.1007/978-1-59745-205-2_8 摘要:Thompson MD, Siminovitch KA, Cole DE. G protein-coupled receptor pharmacogenetics. Methods Mol Biol. 2008;448():139–85. doi: 10.1007/978-1-59745-205-2_8. 参考文献:10.1007/bf03257158 摘要:Dogné JM, de Leval X, Benoit P, Delarge J, Masereel B. Thromboxane A2 inhibition: therapeutic potential in bronchial asthma. Am J Respir Med. 2002;1(1):11–7. doi: 10.1007/bf03257158.